Hong Jae Chon, Director of Cancer Center, CHA Bundang Medical Center, shared on X:
“Deep response as a novel efficacy endpoint in HCC: New editorial by Masatoshi Kudo on Liver Cancer.
- Depth of response (DpR) shows strong correlation with OS across multiple phase 3 ICI-based trials
- IMbrave150: DRR60 (≥60% shrinkage) achieved in 21% with Atezo+Bev
- HIMALAYA: pts achieving ≥75% shrinkage reached 83.3% 5-yr OS vs 11.1% with <30% shrinkage
- CheckMate9DW: DRR60 reached 30%, with median OS not reached in this subgroup
- TALENTACE: Adding LRT to systemic therapy can further deepen response and improve OS”
Title: Deep Response as a Novel Efficacy Endpoint in Hepatocellular Carcinoma
Authors: Masatoshi Kudo
You can also read: ‘Daraxonrasib Resistance in Pancreatic Cancer Points to New Combination Strategies’
